A phase 1/2 study of JK06, a 5T4 antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancer.Nuria Kotecki, Naimish Pandya, Sylvie Rottey et al.|Journal of Clinical Oncology|2025Cited by 0
Abstract CT250: A phase 1b / 2 study of JK06, a 5T4-targeted antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancerOmar Saavedra, Nuria Kotecki, B. Dekeyser et al.|Cancer Research|2026Cited by 0
A phase 1b/2 study of JK06, a 5T4-targeted antibody-drug conjugate (ADC), in patients with unresectable locally advanced or metastatic cancer.Omar Saavedra, Nuria Kotecki, Fabricio Racca et al.|Journal of Clinical Oncology|2026Cited by 0